FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Workshop on Patient Experience Data

Federal Register notice: FDA announces a 12/13 virtual public workshop entitled Patient-Focused Drug Development: Workshop to Discuss Methodologic and...

latest-news-card-1
Human Drugs

Boston Scientific Recalls Cryoablation Catheters

Boston Scientific recalls (Class 1) its POLARx and POLARx FIT Cryoablation Balloon Catheters because of atrio-esophageal fistula risks.

latest-news-card-1
Medical Devices

LivaNova Sleep Apnea Device Meets Endpoints

LivaNova says its aura6000 obstructive sleep apnea treatment met the safety and efficacy endpoints in the OSPREY trial in adults.

latest-news-card-1

FDA Needs Inspection Staff Recruitment Plan: GAO

GAO healthcare director Mary Denigan-Macauley says FDA needs a plan and a strategy for recruiting and retaining new facility inspectors.

Medical Devices

FDA Clears GEs Head-Only MRI Device

FDA clears a GE HealthCare 510(k) for its Signa Magnus, a 3.0T high-performance, head-only MRI scanner.

latest-news-card-1
Biologics

Adaptimmune Therapeutics Plan Lete-Cel BLA

Adaptimmune Therapeutics plans a rolling BLA submission for cell therapy lete-cel in certain people with synovial sarcoma or myxoid/round cell liposar...

latest-news-card-1
Human Drugs

7 Observations on U.S. Specialty FDA-483

FDA releases the form FDA-483 with seven observations from an inspection at the U.S. Specialty Formulations outsourcing facility in Allentown, PA.

latest-news-card-1
Human Drugs

Oligonucleotide-Based Therapeutic Assessment

FDA publishes a draft guidance on the nonclinical safety assessment of oligonucleotide-based therapeutics.

latest-news-card-1
Medical Devices

NovaBone Putty Cleared for Intervertebral Disc Repair

FDA clears a NovaBone Products 510(k) for its NovaBone Putty and its expanded use in the intervertebral disc space.

latest-news-card-1

SCOTUS Decisions Effect on FDA Analyzed

Six Squire Patton Boggs attorneys lay out the impact of four recent Supreme Court decisions on several aspects of FDA regulation.